Heterogeneity of Anti-Phospholipid and Anti-Endothelial Cell Antibodies

Shan, Hua; Goldman, J; Cunto, Gina; Manuppello, J R; Chaiken, Irwin M.; Cines, Douglas B.; Silberstein, Leslie E.

doi:10.1006/jaut.1998.0242

Cited by 10 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these proteins were neither identified nor were they specific for endothelial cells, since antigens of the same sizes were immunoprecipitated from fibroblasts as well. In this light, it is possible that AECA, in contrast to what their name suggests, are not truly endothelial-cell specific and the continuing search for endothelial autoantigens might not lead to the results desired [32].…”

Section: Discussionmentioning

confidence: 97%

Vitronectin- and Fibronectin-containing Immune Complexes in Primary Systemic Vasculitis

Maehnss

Kobarg

Schmitt

et al. 2002

Journal of Autoimmunity

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Vitronectin- and Fibronectin-containing Immune Complexes in Primary Systemic Vasculitis

Maehnss

Kobarg

Schmitt

et al. 2002

Journal of Autoimmunity

View full text Add to dashboard Cite

“…The other significant difference was the higher incidence of multiple antibodies (!3) in APS (75%) compared to ITP (57%), P < 0.05. Other investigators have also reported multiple APLA in patients with APS [10,25,26]. To account for this, it is possible that the greater diversity of tissues in target organs in APS or SLE [27][28][29][30] to generate multiple antibodies, while in ITP, the target is restricted to platelets, their glycoproteins, and altered platelet membrane as discussed above.…”

Section: Discussionmentioning

confidence: 97%

Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS)

Bidot

Horstman

et al. 2006

Am. J. Hematol.

View full text Add to dashboard Cite

Antiphospholipid antibodies (APLA) are associated with anti-phospholipid syndrome (APS), a thrombotic disorder, but they are also frequently detected in immune thrombocytopenic purpura (ITP), a bleeding disorder. To investigate possible differences of APLA between these two disorders, we assayed IgG and IgM APLA by ELISA in 21 patients with ITP and 33 with APS. The APLA reacting against two protein target antigens, b 2 -glycoprotein 1 (b2GP1) and FVII/VIIa, and four phospholipids [cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE)] as well as lupus anticoagulant (LA) were analyzed. We made the following observations: (i) IgG and IgM antibodies to b2GP1 and IgM antibodies to FVII/VIIa were more common in APS than ITP, P < 0.05, while IgG antibodies against the phospholipids (aCL, aPC, aPS, aPE) were more common in ITP than APS, P < 0.05; (ii) multiple APLA (≥3 antigens) were more frequent in APS than ITP, P < 0.05; (iii) LA was frequently associated with APS but was absent in ITP; (iv) APLA is quite common in ITP: two-thirds were positive for at least one APLA. In summary, APLA are prevalent in ITP but their profile differs from APS. In APS, antibodies were predominantly against b2GP1 and

show abstract

“…A number of human aPL mAbs from APLS patients, from a chronic lymphocytic leukaemia (CLL) patient and from a few normal individuals have been obtained (Rauch et al , 1987; Bakimer et al , 1992; Van Es et al , 1992; Mariette et al , 1993; Ichikawa et al , 1994; Demaison et al , 1995; Harmer et al , 1995; Wang et al , 1995; Olee et al , 1996; Menon et al , 1997; Takeya et al , 1997; George et al , 1998; Ikematsu et al , 1998; Lai et al , 1998; Shan et al , 1998; Zhu et al , 1999). These mAbs are representative of a wide array of different anti‐PL antibody specificities, but none exhibited the antigen specificity features of IgMλ‐FRO.…”

Section: Discussionmentioning

confidence: 99%

“…Data on the Ig V‐region genes used by a number of aPL human mAbs derived from patients with APLS, a patient with CLL and from a few normal individuals are available (Van Es et al , 1992; Mariette et al , 1993; Demaison et al , 1995; Harmer et al , 1995; Hohmann et al , 1995; Menon et al , 1997; Ikematsu et al , 1998; Lai et al , 1998; Shan et al , 1998; Chukwuocha et al , 1999). The antigen specificity features of IgMλ‐FRO are unique among these mAbs and therefore this is first characterization of rearranged Ig V‐region genes encoding a true aAPL IgM antibody exerting LA activity and lacking polyreactivity with DNA and other autoantigens.…”

Section: Discussionmentioning

confidence: 99%

True anti‐anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity

Gallart¹,

Benito

Reverter³

et al. 2002

Br J Haematol

View full text Add to dashboard Cite

Summary. True (cofactor-independent) anticardiolipin antibodies (aCL) are thought to lack lupus anticoagulant (LA) activity and pathogenic potential. A serum monoclonal immunoglobulin Mk (mIgMk) with aCL and LA activities found in a man with a splenicIgMk + B-cell lymphoplasmacytic lymphoma (LPL) without thrombotic events has been characterized. LPL-derived hybridoma clones (designated HY-FRO) producing the serum mIgMk were obtained. mIgMk secreted by HY-FRO grown in protein-free culture medium, like that purified from serum, (i) showed binding, in a cofactor-free system, to solid-phase CL and phosphatidylserine (PS) and to the membrane of PS-expressing cells (apoptotic cells and activated platelets); (ii) failed to bind neutral phospholipids (PL), b 2 Glycoprotein, histone, ssDNA, dsDNA, human IgG and umbilical vein endothelial cells. Absorption with apoptotic cells abolished its binding to anionic plate-bound CL and PS. IgMk-FRO used poorly mutated VH and Vk region genes, with a pattern that was inconsistent with an antigen-driven selection. Basic amino acids were present in the IgH complementarity determining region 3 (CDR3), which can be important for binding to anionic PL. These findings demonstrate unequivocally that true anti-anionic PL IgM antibodies can exert LA and indicate this anti-PL type does not involve thrombophilia.

show abstract

Heterogeneity of Anti-Phospholipid and Anti-Endothelial Cell Antibodies

Cited by 10 publications

References 25 publications

Vitronectin- and Fibronectin-containing Immune Complexes in Primary Systemic Vasculitis

Vitronectin- and Fibronectin-containing Immune Complexes in Primary Systemic Vasculitis

Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS)

True anti‐anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity

Contact Info

Product

Resources

About